



**Königs C, Ozelo MC, Dunn A, et al. First study of extended half-life rFVIII Fc in previously untreated patients with hemophilia A: PUPs A-LONG final results. *Blood*. 2022;139(26):3699-3707.**

On page 3699, in the first sentence of "Introduction," "Hemophilia AQ7 A" should read "Hemophilia A."

<https://doi.org/10.1182/blood.2022019369>

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

---

**Johnston RL, Mottok A, Chan FC, et al. A gene expression–based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma. *Blood*. 2022;139(6):889-893.**

In the original online version of the article, supplemental File 3 was a file from another article. The correct supplemental file was later inserted. The publisher apologizes for the error.

<https://doi.org/10.1182/blood.2023019882>

© 2023 by The American Society of Hematology

---

**Lee JB, Khan DH, Hurren R, et al. Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production. *Blood*. 2021;138(3):234-245.**

In the conflict-of-interest disclosure paragraph on page 244, the following disclosure for Li Zhang should have been included: holds stock in WYZE Biotech Co Ltd.

<https://doi.org/10.1182/blood.2023019985>

© 2023 by The American Society of Hematology